Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Citrome, L. Articles by Lieberman, J. A. Search for Related Content PubMed Citation Articles by Citrome, L. Articles by Lieberman, J. A. Hospitals, Hospital Treatment Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders

Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia

OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.

This article has been cited by other articles:

				A. Wheeler, V. Humberstone, and G. Robinson Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol, November 1, 2009; 23(8): 957 - 965. [Abstract] [PDF]

				M. J. Hoptman, J. Volavka, P. Czobor, G. Gerig, M. Chakos, J. Blocher, L. L. Citrome, B. Sheitman, J.-P. Lindenmayer, J. A. Lieberman, et al. Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder J Neuropsychiatry Clin Neurosci, November 1, 2006; 18(4): 509 - 515. [Abstract] [Full Text] [PDF]

				M. I. Krakowski, P. Czobor, L. Citrome, N. Bark, and T. B. Cooper Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, June 1, 2006; 63(6): 622 - 629. [Abstract] [Full Text] [PDF]

				J. E. Kraus and B. B. Sheitman Clozapine Reduces Violent Behavior in Heterogeneous Diagnostic Groups J Neuropsychiatry Clin Neurosci, February 1, 2005; 17(1): 36 - 44. [Abstract] [Full Text] [PDF]

				L. Citrome Antihostility Effects of Adjunctive Divalproex Psychiatr Serv, September 1, 2004; 55(9): 1068 - 1069. [Full Text] [PDF]

				L. Citrome, D. E. Casey, D. G. Daniel, P. Wozniak, L. D. Kochan, and K. A. Tracy Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone Psychiatr Serv, March 1, 2004; 55(3): 290 - 294. [Abstract] [Full Text] [PDF]

				D. W. Bradford, T. S. Stroup, and G. V. L. De Socio Schizophrenia, Drug Therapy, and Monitoring N. Engl. J. Med., January 22, 2004; 350(4): 415 - 416. [Full Text] [PDF]

				M. Fayek, C. Flowers, D. Signorelli, and G. Simpson Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry Psychiatr Serv, November 1, 2003; 54(11): 1453 - 1456. [Full Text] [PDF]

				A. S. Bassett, E. W.C. Chow, P. AbdelMalik, M. Gheorghiu, J. Husted, and R. Weksberg The Schizophrenia Phenotype in 22q11 Deletion Syndrome Am J Psychiatry, September 1, 2003; 160(9): 1580 - 1586. [Abstract] [Full Text] [PDF]

				J. E. C. Hallak, S. M. Dursun, R. Guarnieri, E. Almeida, K. Rezeck, J. A. S. Crippa, A. C. Sakamoto, A. W. Zuardi, and J. F. W. Deakin Olanzapine for Recurrent Aggression in a Patient with Temporal Lobe Epilepsy who had Temporal Lobectomy J Psychopharmacol, September 1, 2003; 17(3): 350 - 351. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us